Navigation Links
AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
Date:11/24/2009

ase 2 program. Along with the recently disclosed positive results for the ovarian cancer indication, the good news for the endometrial cancer indication provides us with an even stronger basis to take the next steps in the development of AEZS-108 in gynaecological cancers."

About AEZS-108 and its Phase 2 program

AEZS-108 represents a new targeting concept in oncology using a cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors, results in its accumulation and preferential uptake in the malignant tissue.

In a Phase 2 study program entitled, "The antitumoral activity and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin in women with LHRH-receptor positive gynaecological tumors", patients with tumors expressing LHRH receptors are administered an intravenous infusion of 267 mg/m2 of AEZS-108 over a period of 2 hours, every Day 1 of a 21-day (3-week) cycle. The proposed duration of the study treatment is 6, 3-week cycles.

Study AGO-GYN 5 is performed with 14 centers of the German Gynaecological Oncology Working Group (AGO; www.ago-ovar.de), in cooperation with 3 clinical sites in Europe.

The program was planned to include up to 82 evaluable patients, up to 41 with a diagnosis of platinum-resistant and taxane-pretreated ovarian cancer, (for which positive results were disclosed on November 2, 2009) and up to 41 with advanced or recurrent endometrial cancer. For both indications, patient recruitment was planned in 2 stages, with 21 and 20 patients, respectively, and the primary efficacy endpoint at the end of stage 2 was defined as 5 or more patients with
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... -- Wockhardt Limited today announces a major boost to ... two of its drugs, WCK 771 and WCK 2349, ... from U.S. Food & Drug Administration (FDA).  QIDP status ... have a high degree of unmet need in their ... (a top U.S. government health and safety body).  QIDP ...
(Date:8/31/2014)... 31, 2014 2014 Market ... a professional and in-depth research report on ... Polyacrylamide information, including Polyacrylamide definition, classification, application, ... industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment ...
(Date:8/30/2014)... 31, 2014 The Global and ... and in-depth study on the current state of ... China. , The report provides a basic overview ... chain structure. Global market analysis and Chinese domestic ... history, developments, trends and competitive landscape of the ...
(Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2
... CARLSBAD, Calif., Dec. 14 Isis,Pharmaceuticals, Inc. (Nasdaq: ... of,Directors has promoted B. Lynne Parshall, J.D. to ... position as Chief Financial,Officer, and is a Director ... and appropriately reflects the scope,of Lynne,s responsibilities at ...
... /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; Nasdaq: PXSL) today announced ... its asthma diagnostic tool, Aridol in Portugal., ... included in the,successful mutual recognition procedure earlier this ... "Bronchial challenge testing is a common procedure ...
... Corporation (NYSE:,FMC) and Pronova BioPharma ASA (OSE: ... a worldwide license and development agreement to ... by FMC. The,alginate-based capsule technology is expected ... Pronova BioPharma,s products and has,the potential for ...
Cached Biology Technology:Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 2Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 3Pharmaxis Appoints Portuguese Distributor for Aridol 2FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 2FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 3FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 4
(Date:9/2/2014)... The Field Museum will present the prestigious Parker/Gentry Award ... commitment to biodiversity conservation awareness. The Parker/Gentry Award is ... individual, team or organization whose efforts have had a ... and whose actions can serve as a model to ... an environmental science and conservation news website that draws ...
(Date:9/2/2014)... a history of scientific research on mountain ecosystems, ... systems, and sets an agenda for biodiversity conservation ... "Mountain gloom and mountain glory revisited: A survey ... regions," appears online in the Journal of ... of Tufts University, Jodi A. Hilty of the ...
(Date:9/2/2014)... JUPITER, FL, September 2, 2014 In a new ... scientists from the Florida campus of The Scripps Research ... diseased cells into unique manufacturing sites for molecules that ... using a cell as a reaction vessel and a ... in a diseased cell," said TSRI Professor Matthew Disney.,"Because ...
Breaking Biology News(10 mins):An uphill climb for mountain species? 2An uphill climb for mountain species? 3Scripps Florida scientists make diseased cells synthesize their own drug 2
... turtles are too optimistic, according to Loren McClenachan ... McClenachan, Jeremy Jackson and Marah Newman agree ... helped increase green and hawksbill turtle populations that ... that dwindling turtle populations on many historically important ...
... population in New Hampshire's Great Bay estuary has plummeted by ... disease MSX. The previous century saw a slower but equally ... local extinction on some reefs," says Ray Grizzle, research associate ... , Now Grizzle is working to bring oysters back ...
... a surprisingly high percentage of people with type 1 ... years or longer (The Joslin Medalists) may still have ... The findings will be presented June 12 at the ... Washington, D.C. , "It is surprising that some ...
Cached Biology News:All the eggs in one basket 2All the eggs in one basket 3UNH researcher restoring oyster reefs to Great Bay 2Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes 2Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes 3